Skip to main content
Clinical Trials/NL-OMON55871
NL-OMON55871
Completed
Phase 2

A prospective follow-up Intervention Study: Detection of Early Esophageal Cancer by Near-Infrared Fluorescence molecular Endoscopy using Bevacizumab-800CW - Detection of Early Esophageal Cancer by NIR-FME. ESCEND

niversitair Medisch Centrum Groningen0 sites25 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
niversitair Medisch Centrum Groningen
Enrollment
25
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
October 17, 2022
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Suspicion or diagnosed LGD, HGD or superficial EAC and planned diagnostic
  • and/or therapeutic \- endoscopy.
  • \- Age: 18 years or older.
  • \- Written informed consent.

Exclusion Criteria

  • \- Patients younger than 18 years old
  • \- Submucosal and invasive EAC; EAC with TNM\-classification other than T1\.
  • \- Radiation therapy for esophageal cancer
  • \- Immunoglobulin allergy
  • \- Chemotherapy, immunotherapy or surgery 28 days before administration of the
  • \- Prior Bevacizumab or Cetuximab treatment
  • \- Patients using anti\-epileptic drugs (only exclusion criterium for the ICG
  • \- Non\-adjustable hypertension
  • \- Medical or psychiatric conditions that compromise the patient\*s ability to
  • give informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials